Following recent approvals of ADASUVE, Alexza Pharmaceuticals, Inc. (ALXA) CEO Thomas King says the company is focusing renewed attention on developing new drugs. King says ADASUVE’s combination of an effective drug with the company’s Staccato system can be a model for changing other standard-of-care regiments. He says the Staccato technology’s speed, predictability and non-invasive delivery system make it ideal for treating acute and intermittent conditions that are dependent on speed and patient control.
“The next product in our pipeline is AZ-002, also known as Staccato alprazolam,” King says. “This product leverages the Staccato attributes, and we hope to see clinical evidence of its efficacy in treating acute repetitive seizures, which is an important subset of patients with epilepsy. We expect to start a Phase II proof-of-concept study with AZ-002 this quarter.”
FOR MORE INFORMATION ON THIS INTERVIEW CLICK HERE.
In addition, King says Alexza Pharmaceuticals is also investigating other products for possible clinical development. He sys the Staccato drug delivery technology will drive the product pipeline.
“So 2014 is exciting from a pipeline perspective, because for the first time in several years, we’re getting to put a product back into clinical development, and we look to see data from that clinical trial in 2015,” King says.
Regeneron Pharmaceuticals Inc (REGN) to Continue Growth with Ocular Drug EYLEA and Rich Antibody Pipeline
September 19, 2013
Active Pipeline Sustains Growth for Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
April 12, 2016
AcelRx Pharmaceuticals Inc (ACRX) Prepares to Launch Lead Product Zalviso to Manage Postoperative Pain Nonintravenously
August 22, 2013
American Campus Communities, Inc. (ACC) Says Combined Development Pipeline for 2015 and 2016 is $437 Million
October 31, 2014
Amgen, Inc. (AMGN) Underappreciated with Emerging Pipeline Story
January 23, 2015
